Arbutus Announces Changes to Board of Directors and Appointment of Lindsay Androski as CEO

Core Viewpoint - Arbutus Biopharma Corporation has announced significant changes in its leadership, including the appointment of Lindsay Androski as the new CEO, aimed at enhancing the company's focus on its pipeline and LNP delivery technology [1][3]. Leadership Changes - Lindsay Androski has been appointed as the new CEO, replacing Michael J. McElhaugh, effective immediately [1]. - Four new directors have joined the board: Robert Alan Beardsley, Joseph Bishop, Matthew Gline, and Anuj Hasija, while all existing board members have stepped down [3]. - The board has been reduced to five members, with potential plans to expand in the future to include expertise in clinical development [3]. Strategic Focus - The company will temporarily pause participation in investor meetings and conferences to review development plans and strategic options for its hepatitis B programs [4]. - The leadership changes are expected to enable a renewed focus on advancing the company's pipeline and maximizing contributions to LNP delivery technology through Genevant [3]. Company Overview - Arbutus Biopharma Corporation is a clinical-stage biopharmaceutical company focused on infectious diseases, currently developing imdusiran (AB-729) for chronic hepatitis B [5]. - The company aims to leverage its ownership stake and license agreement with Genevant to enhance its LNP delivery technology [5].